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To the Editor
We read with great interest the Letter to the Editor by Richards et. al. (1), published in 
response to our article on synthetic cathinones, or “bath salts” (2). While we applaud the 
authors attempt to shed some light on the controversial use of selective β-adrenergic receptor 
antagonists as treatment for toxicity produced by sympathomimetic agents such as the 
synthetic cathinones, several statement and claims made by Richards et al., require further 
clarification. Richards et al., state that they… “routinely utilize intravenous labetalol, a 
mixed α- and β-blocker, in the treatment of methamphetamine, cocaine and “bath salt” 
patients, with excellent results.” Importantly and underemphasized by these authors is the 
fact that labetalol possess α-adrenergic receptor antagonistic properties. Additionally, we 
outlined the important role activation of α- and β-adrenergic receptors play in the 
cardiovascular and hyperthermic responses seen to sympathomimetic agents such as the 
synthetic cathinones.
Previously, we had shown in a preclinical model that β-adrenergic receptor antagonists 
devoid of α-adrenergic receptor antagonistic properties were not affective in attenuating the 
hyperthermia induced by the sympathomimetic agent, 3,4-
methylenedioxymethamphetamine (MDMA, 3). In this same study, we demonstrated that 
carvedilol, an α1- and β1,2,3-adrenergic could attenuate MDMA-induced hyperthermia and 
subsequent rhabdomyolysis (3). Subsequent to our findings with carvedilol, Hysek et al., (4) 
demonstrated in healthy human subjects that carvedilol could reverse MDMA-mediated 
increases in blood pressure, heart rate and body temperature. Hysek et al., (5) had previously 
demonstrated in healthy human subjects that the non-selective β-adrenergic receptor 
antagonist (devoid of α-adrenergic receptor activity), pindolol, inhibited MDMA-induced 
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increases in heart rate but was ineffective at preventing the increase in mean arterial blood 
pressure. These studies indicate that β-adrenergic receptor antagonism without α-adrenergic 
antagonism is ineffective at reversing the hemodynamic and hyperthermic effects of 
MDMA. Thus, the positive outcomes seen by Richards et al., through the use of labetalol is 
predictable and consistent with recommendations by the American Heart Association/
American College of Cardiology Foundation Guidelines (6) supporting the use of a 
combined α- and β-adrenergic receptor antagonist, such as labetalol or carvedilol, as a 
treatment option for myocardial infarction and unstable angina induced by cocaine and 
methamphetamine.
Based on these preclinical and human data and the current Guidelines (6), we would suggest 
physicians avoid a non-discriminating approach to selecting β-blockers in treating patients 
with sympathomimetic exposure and use a combined α- and β-adrenergic receptor 
antagonist such as labetalol or carvedilol (6). All β-blockers are not created equal as 
Richards et al, letter may have inadvertently suggested.
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